• Shi Chen, Jing-Hui Hou, Xing-Yu Feng, Xiao-Shi Zhang, Zhi-Wei Zhou, Jing-Ping Yun, Ying-Bo Chen, and Mu-Yan Cai.
• The State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, China.
• J Surg Oncol. 2013 Jun 1;107(8):799-806.

Background And ObjectivesCD44 and CD133 have been reported as putative stem cell markers. However, the clinicopathologic significance of CD44 and CD133 expression in patients with gastric carcinoma (GC) has not been clearly elucidated.MethodsImmunohistochemistry (IHC) was performed to investigate the CD44 and CD133 expression in gastric carcinomas and normal mucosal tissues. Receiver operating characteristic (ROC) curve analysis, spearman's rank correlation, Kaplan-Meier plots, and Cox proportional hazards regression model were used to analyze the data.ResultsThe highly expressed CD44 and CD133 were observed in 27/152 (17.7%) and 64/152 (42.1%) of GCs and in 4/60 (6.7%) and 15/60 (25.0%) normal gastric mucosal tissues, respectively (P < 0.05, Fisher's exact test). High expression of CD44 was significantly correlated with tumor poorer differentiation, presence of distant metastasis, advanced TNM stage, and tumor relapse; and high expression of CD133 was positively associated with tumor invasion depth, presence of distant metastasis and advanced TNM stage. More importantly, high-expressed CD44 and CD133 were both associated with shorter survival as evidenced by univariate and multivariate analysis.ConclusionsOur study introduces high expression of CD44 and CD133 as adverse independent prognostic factors in GC patients. The combined CD44 and CD133 expression may become a useful tool for identifying patients with different clinical outcomes.Copyright © 2013 Wiley Periodicals, Inc.

32 keywords...

hide…